Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway

KIORA PHARMACEUTICALS INC

Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.
Cash, equivalents and short-term investments of $17.1M as of Dec 31, 2025; expects runway into late 2027.
KIO-301 Phase 2 ABACUS-2 trial for retinitis pigmentosa advancing; initial data readout expected Q3 2027.
KIO-104 Phase 2 KLARITY trial for macular edema dosing; non-cash impairment charge in Q4.
Executed option agreement with Senju for KIO-301 in Asia with potential value up to $110M plus royalties.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

KIORA PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2025 results: net income The Company reported a net loss of $6.5 million in the fourth quarter of 2025, compared with a net loss of $4.2 million.

Period: the fourth quarter and full year ended December 31, 2025
Net income: The Company reported a net loss of $6.5 million in the fourth quarter of 2025, compared with a net loss of $4.2 million
Result: reported results

Exact text from the filing

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

View on SEC.gov

Browse all earnings releases →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.